Corvus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Corvus Pharmaceuticals generated cash of -$23,935,000, which is more than the previous year. Cash used in financing activities reached the amount of $7,855,000 last year. Net change in cash is therefore -$539,000.
Cash Flow
| 2015 | -11.32M | -92.03M | 94.94M |
|---|---|---|---|
| 2016 | -27.85M | -42.55M | 71.35M |
| 2017 | -46.21M | 84.82M | 1.44M |
| 2018 | -40.98M | -30.19M | 65.27M |
| 2019 | -37.32M | 3.25M | 24K |
| 2020 | -34.77M | 44.76M | 1.31M |
| 2021 | -36.71M | 21.56M | 62.15M |
| 2022 | -27.02M | -23.27M | 0 |
| 2023 | -23.93M | 15.54M | 7.85M |
CRVS Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.15M | 63.45M | 16.45M | 5.15M | 39.19M | 45.10M | 5.05M | 4.10M | 12.51M |
Operating activities | |||||||||
Net income | -27.02M | -41.30M | -43.24M | -5.99M | -46.67M | -46.93M | -55.66M | -36.37M | -31.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 151K | 367K | 460K | 632K | 743K | 847K | 842K | 594K | 148K |
Stock-based compensation expense | 2.14M | 2.69M | 4.23M | 5.74M | 7.34M | 0 | 6.22M | 3.82M | 428K |
| Deferred income tax benefit | 2.14M | 2.69M | 4.23M | 5.74M | 7.34M | 0 | 6.22M | 3.82M | 428K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 562K | -81K | -507K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -451K | 411K | -1.90M | 1.01M | 450K | -1.45M | 1.55M | 518K | 1.24M |
Cash generated by operating activities | -23.93M | -27.02M | -36.71M | -34.77M | -37.32M | -40.98M | -46.21M | -27.85M | -11.32M |
Investing activities | |||||||||
Purchases Of Investments | -47.04M | -66.19M | -9.35M | -42.54M | -138.58M | -161.86M | -88.30M | -258.28M | -104.38M |
Investments In Property Plant And Equipment | -34K | -269K | -5K | -76K | -25K | -355K | -266K | -2.19M | -1.74M |
Acquisitions Net | 0 | 22K | -21.56K | -44.84K | -3.28K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 15.54M | -23.27M | 21.56M | 44.76M | 3.25M | -30.19M | 84.82M | -42.55M | -92.03M |
Financing activities | |||||||||
Common Stock Issued | 7.84M | 0 | 62.15M | 1.22M | 24K | 64.87M | 711K | 0 | 94.94M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 7.85M | 0 | 62.15M | 1.31M | 24K | 65.27M | 1.44M | 71.35M | 94.94M |
Net Change In Cash | -539K | -50.29M | 47.00M | 11.30M | -34.04M | -5.91M | 40.05M | 945K | -8.41M |
Cash at end of period | 12.62M | 13.15M | 63.45M | 16.45M | 5.15M | 39.19M | 45.10M | 5.05M | 4.10M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |